<PAGE>

             [PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A
             REQUEST FOR CONFIDENTIALITY UNDER RULE 24b-2 OF THE
             SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. A COPY OF THIS
             AGREEMENT WITH THIS EXHIBIT INTACT HAS BEEN FILED SEPARATELY
             WITH THE SECURITIES AND EXCHANGE COMMISSION.]

                               FIRST AMENDMENT TO
                           EXCLUSIVE LICENSE AGREEMENT
                                       FOR
            SELECTED APPLICATIONS OF COATED NANOCRYSTALLINE PARTICLES




                                     BETWEEN




                   THE REGENTS OF THE UNIVERSITY OF CALIFORNIA





                                       AND





                          BEN-ABRAHAM TECHNOLOGIES INC.





                               UC CASE NO. 89-204

<PAGE>

               FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT
         FOR SELECTED APPLICATIONS OF COATED NANOCRYSTALLINE PARTICLES

         This amendment ("Amendment") is effective this 26th day of October,
1999, by and between The Regents of the University of California ("The
Regents"), a California corporation, having its statewide administrative
offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200,
and Ben-Abraham Technologies Inc. ("Licensee"), a Wyoming corporation, having
a principal place of business at 175 Olde Half Day Road, Suite 123,
Lincolnshire, Illinois 60069.

                                    RECITALS

         Whereas, Licensee and The Regents entered into a license agreement
entitled "Exclusive License Agreement for Selected Applications of Coated
Nanocrystalline Particles," effective on June 18, 1997, having U.C. Agreement
Control Number 1997-04-0671 ("License Agreement"), covering licensure to
Licensee by The Regents of rights in certain inventions developed by Dr. Nir
Kossovsky et al. at the University of California, Los Angeles and covered by
Patent Rights (as defined in the License Agreement);

         Whereas, although Licensee and The Regents both agree that the other
party has substantially complied with the terms of the License Agreement,
changed circumstances have necessitated that certain other provisions of the
License Agreement be modified and amended;

         Whereas, Licensee has requested that The Regents amend certain
provisions in the License Agreement to a more financial and time feasible
schedule; and

         Whereas, The Regents is willing to amend the License Agreement to
reflect such request.

         Now, Therefore, in consideration of the foregoing and the mutual
promises and covenants contained herein, the parties hereto agree as follows:

<PAGE>

1.       Paragraph 1.6 (Definitions) of the License Agreement is deleted in its
         entirety and replaced with the following:

                  "1.6     Drug Delivery  System" means coated  nanocrystalline
                   particles  used in  pharmaceutical preparations to facilitate
                   the therapeutic delivery of insulin in humans."

2.       Paragraph 1.7 (Definition) of the License Agreement is deleted in its
         entirety and replaced with the following:

                  "1.7     [reserved]."

3.       Paragraph 1.8 (Definitions) of the License Agreement is deleted in its
         entirety and replaced with the following:

                  "1.8     "Field" means Vaccine Adjuvant, Virus Vaccine
                  Construct, and Drug Delivery System."

4.       Paragraph 1.13 (Definitions) is added to the License Agreement
         as follows:

                  "1.13 "Project" means the Vaccine Adjuvant project specified
         in Subparagraph 5.9a, Epstein Barr Vaccine project specified in
         Subparagraph 5.9b, Herpes 2 Vaccine project specified in Subparagraph
         5.9c, HIV Vaccine project specified in Subparagraph 5.9d, and Insulin
         project specified in Subparagraph 5.9e."

5.       Paragraph 4.5 (Royalties) of the License Agreement is deleted in its
         entirety and replaced with the following:

                  "4.5 Beginning in the year 2004, Licensee will pay to The
         Regents a minimum annual royalty in the amounts and at the times set
         forth below:


<TABLE>
                             <S>                            <C>
                             2004                             $  50,000
                             2005                             $ 100,000
                             2006                             $ 150,000
                             2007                             $ 200,000
                             2008                             $ 400,000
                             2009                             $ 600,000
                             2010                             $ 800,000
                             2011                           $ 1,500,000
</TABLE>



                                       2
<PAGE>

         In each succeeding calendar year after the year 2011, Licensee will pay
         a minimum annual royalty of One Million Five Hundred Thousand Dollars
         ($1,500,000) and thereafter for the life of this Agreement. This
         minimum annual royalty will be paid to The Regents by February 28 of
         the year following accrual of the royalties and will be credited
         against the earned royalty due and owing for the calendar year in which
         the minimum payment was made."

5.       Paragraph 5.7 (Due Diligence) of the License Agreement is deleted in
         its entirety and replaced with the following:

                  "5.7     Licensee must hire the following key employees or
         independent contractors by the designated dates:

<TABLE>
<CAPTION>
------------------------------------------------------------ ------------------ --------------------------------------
                   Position Description                         # Req.                  Hiring Target Date
------------------------------------------------------------ ------------------ --------------------------------------
<S>                                                          <C>                <C>
Director, Research & Development                                     1                  December 1, 1996
Senior Vaccine Development Specialist                                1                  June 30, 1997
Senior Pharmaceutical Development Specialist                         1                  June 30, 1997
Process Development Scientist                                        1                  April 30, 1997
Quality Control/Assurance Manager                                    1                  December 31, 1997
Information Management Systems Specialist                            1                  December 31, 1997
Regulatory Specialist                                                1                  December 31, 1998

</TABLE>



6.       Paragraph 5.8 (Due Diligence) of the License Agreement is deleted in
         its entirety and replaced with the following:

         "5.8 In the hiring of key employees or independent contractors
designated in Paragraph 5.7 above, Licensee will use the criteria set forth
and hire qualified candidates.

                                       3
<PAGE>


7.       Sub-paragraph 5.9a (Due Diligence) of the License Agreement is deleted
         in its entirety and replaced with the following:

                          5.9a Vaccine Adjuvant Project


<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------
                MILESTONES #                                                   TARGET DATE
<S>                                                                       <C>
-------------------------------------------------------------------------------------------------
1:  Produce a Patent Product comprising Vaccine Adjuvant for test              September 30, 1997
purposes
-------------------------------------------------------------------------------------------------
2:  Produce a test model for a Patent Product comprising Vaccine               February 28, 1998
Adjuvant
-------------------------------------------------------------------------------------------------
3:  Complete toxicity testing for a Patent Product comprising Vaccine          September 30, 1998
Adjuvant
-------------------------------------------------------------------------------------------------
4:  Enter into strategic alliances or sublicenses for the development of a     January 31, 2000
Patent Product comprising Vaccine Adjuvant
-------------------------------------------------------------------------------------------------
5:  Submit IND in the United States and the foreign regulatory
counterpart in Europe and Japan for a Patent Product comprising
Vaccine Adjuvant
-------------------------------------------------------------------------------------------------
6:  Begin Phase I Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Vaccine Adjuvant
-------------------------------------------------------------------------------------------------
7:  Begin Phase 2/3 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Vaccine Adjuvant
-------------------------------------------------------------------------------------------------
8:  File for marketing approval in the United States, Germany, France,
England, and Japan for a Patent Product comprising Vaccine Adjuvant
-------------------------------------------------------------------------------------------------
9:  Introduce a Patent Product comprising Vaccine Adjuvant to the
market in the United States, Germany, and France within 6 months from
marketing approval
-------------------------------------------------------------------------------------------------
10: Fill market demand in each country within 6 months of introduction
for a Patent Product comprising Vaccine Adjuvant
-------------------------------------------------------------------------------------------------
</TABLE>


         [Portions of this Exhibit have been omitted pursuant to a request for
         confidentiality under Rule 24b-2 of the Securities Exchange Act of
         1934, as amended. A copy of this agreement with this Exhibit intact
         has been filed separately with the Securities and Exchange Commission.]

8.       Sub-paragraph 5.9b (Due Diligence) of the License Agreement is deleted
         in its entirety and replaced with the following:

                        5.9b Epstein Barr Vaccine Project

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------
                MILESTONES #                                                   TARGET DATE
<S>                                                                          <C>
-------------------------------------------------------------------------------------------------
1:  Produce a Patent Product comprising Virus Vaccine Construct for the         December 31, 1997
Epstein Barr application
-------------------------------------------------------------------------------------------------
2:  Test a pilot vaccine consisting of a Patent Product comprising Virus        June 30, 1998
Vaccine Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
3:  Complete pre-clinical tests on a Patent Product comprising Virus            December 31, 1998
Vaccine Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
4:  Submit IND in the United States and the foreign regulatory
counterpart in Europe and Japan for a Patent Product comprising Virus
Vaccine Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
5:  Begin Phase I Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
6:  Begin Phase 2 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
7:  Begin Phase 3 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
8:  File for marketing approval in the United States, Germany, France,
England, and Japan for a Patent Product comprising Virus Vaccine
Construct for the Epstein Barr application
-------------------------------------------------------------------------------------------------
9:  Introduce a Patent Product comprising Virus Vaccine Construct for
the Epstein Barr application to the market in the United States,
Germany, France, England, and Japan within 6 months from marketing
approval
-------------------------------------------------------------------------------------------------
10: Fill market demand in each country within 6 months of introduction
for a Patent Product comprising Virus Vaccine Construct for the Epstein
Barr application
-------------------------------------------------------------------------------------------------
</TABLE>


         [Portions of this Exhibit have been omitted pursuant to a request for
         confidentiality under Rule 24b-2 of the Securities Exchange Act of
         1934, as amended. A copy of this agreement with this Exhibit intact
         has been filed separately with the Securities and Exchange Commission.]

9.       Sub-paragraph 5.9c (Due Diligence) of the License Agreement is deleted
         in its entirety and replaced with the following:

                          5.9c Herpes 2 Vaccine Project


<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------
                MILESTONES #                                                   TARGET DATE
<S>                                                                          <C>
-------------------------------------------------------------------------------------------------
1:  Produce a Patent Product comprising Virus Vaccine Construct for the         February 28, 1998
Herpes 2 application
-------------------------------------------------------------------------------------------------
2:  Test a pilot vaccine consisting of a Patent Product comprising Virus        August 31, 1998
Vaccine Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
3:  Complete pre-clinical tests on a Patent Product comprising Virus            February 28, 1999
Vaccine Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
4:  Submit IND in the United States and the foreign regulatory
counterpart in Europe and Japan for a Patent Product comprising Virus
Vaccine Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
5:  Begin Phase I Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
6:  Begin Phase 2 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
7:  Begin Phase 3 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
8:  File for marketing approval in the United States, Germany, France,
England, and Japan for a Patent Product comprising Virus Vaccine
Construct for the Herpes 2 application
-------------------------------------------------------------------------------------------------
9:  Introduce a Patent Product comprising Virus Vaccine Construct for
the Herpes 2 application to the market in the United States, Germany,
France, England, and Japan within 6 months from marketing approval
-------------------------------------------------------------------------------------------------
10: Fill market demand in each country within 6 months of introduction
for a Patent Product comprising Virus Vaccine Construct for the Herpes
2 application
-------------------------------------------------------------------------------------------------
</TABLE>


         [Portions of this Exhibit have been omitted pursuant to a request for
         confidentiality under Rule 24b-2 of the Securities Exchange Act of
         1934, as amended. A copy of this agreement with this Exhibit intact
         has been filed separately with the Securities and Exchange Commission.]


                                       4
<PAGE>

10.      Sub-paragraph 5.9d (Due Diligence) of the License Agreement is deleted
         in its entirety and replaced with the following:

                            5.9d HIV Vaccine Project


<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------
                MILESTONES #                                                   TARGET DATE
<S>                                                                          <C>
-------------------------------------------------------------------------------------------------
1:  Produce a Patent Product comprising Virus Vaccine Construct for the         January 31, 1998
HIV vaccine application
-------------------------------------------------------------------------------------------------
2:  Test a pilot vaccine consisting of a Patent Product comprising Virus        December 31, 1998
Vaccine Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
3:  Complete pre-clinical tests on a Patent Product comprising Virus            May 31, 1999
Vaccine Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
4:  Submit IND in the United States and the foreign regulatory
counterpart in Europe and Japan for a Patent Product comprising Virus
Vaccine Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
5:  Begin Phase I Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
6:  Begin Phase 2 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
7:  Begin Phase 3 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Virus Vaccine Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
8:  File for marketing approval in the United States, Germany, France,
England, and Japan for a Patent Product comprising Virus Vaccine
Construct for the HIV vaccine application
-------------------------------------------------------------------------------------------------
9:  Introduce a Patent Product comprising Virus Vaccine Construct for
the HIV vaccine application to the market in the United States,
Germany, France, England, and Japan within 6 months from marketing
approval
-------------------------------------------------------------------------------------------------
10: Fill market demand in each country within 6 months of introduction
for a Patent Product comprising Virus Vaccine Construct for the HIV
vaccine application
-------------------------------------------------------------------------------------------------
</TABLE>


         [Portions of this Exhibit have been omitted pursuant to a request for
         confidentiality under Rule 24b-2 of the Securities Exchange Act of
         1934, as amended. A copy of this agreement with this Exhibit intact
         has been filed separately with the Securities and Exchange Commission.]

11.      Sub-paragraph 5.9e (Due Diligence) of the License Agreement is deleted
         in its entirety and replaced with the following:

                              5.9e Insulin Project


<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------
                MILESTONES #                                                   TARGET DATE
<S>                                                                          <C>
-------------------------------------------------------------------------------------------------
1:  Produce a Patent Product comprising Drug Delivery System for the            May 31, 1998
insulin application
-------------------------------------------------------------------------------------------------
2:  Test a clinical material consisting of a Patent Product comprising          May 31, 1999
Drug Delivery System for the insulin application
-------------------------------------------------------------------------------------------------
3:  Complete pre-clinical tests on a Patent Product comprising Drug             October 31, 1999
Delivery System for the insulin application
-------------------------------------------------------------------------------------------------
4:  Submit IND for Phase 1 Clinical Trials for use of calcium phosphate
nanoparticles (CAP) as adjuvant or carrier in inhaled or other insulin
application
-------------------------------------------------------------------------------------------------
5:  Submit IND in the United States and the foreign regulatory
counterpart in Europe and Japan for a Patent Product comprising Drug
Delivery System for the insulin application
-------------------------------------------------------------------------------------------------
6:  Begin Phase I Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Drug Delivery System for the insulin application
-------------------------------------------------------------------------------------------------
7:  Begin Phase 2 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Drug Delivery System for the insulin application
-------------------------------------------------------------------------------------------------
8:  Begin Phase 3 Clinical Trials in the United States and the foreign
regulatory counterpart in Europe and Japan for a Patent Product
comprising Drug Delivery System for the insulin application
-------------------------------------------------------------------------------------------------
9:  File for marketing approval in the United States, Germany, France,
England, and Japan for a Patent Product comprising Drug Delivery
System for the insulin application
-------------------------------------------------------------------------------------------------
10: Introduce a Patent Product comprising Drug Delivery System for
the insulin application to the market in the United States, Germany,
France, England, and Japan within 6 months from marketing approval
-------------------------------------------------------------------------------------------------
11: Fill market demand in each country within 6 months of introduction
for a Patent Product comprising Drug Delivery System for the insulin
application
-------------------------------------------------------------------------------------------------
</TABLE>


         [Portions of this Exhibit have been omitted pursuant to a request for
         confidentiality under Rule 24b-2 of the Securities Exchange Act of
         1934, as amended. A copy of this agreement with this Exhibit intact
         has been filed separately with the Securities and Exchange Commission.]

12.      Sub-paragraphs 5.9f, 5.9g and 5.9h (Due Diligence) are deleted in their
         entirety from the License Agreement.

13.      Paragraph 5.11 (Due Diligence) of the License Agreement is deleted in
         its entirety and replaced with the following:

         "5.11 The Regents shall have the right and option to either (1)
terminate this Agreement when Licensee fails to meet due diligence provisions
for any three of the five projects specified under Projects, as defined in
Paragraph 1.13 above; or (2) reduce the exclusive license granted to
non-exclusive licenses for each project specified under Projects, as defined
in Paragraph 1.13 above, when Licensee fails to meet due diligence provisions
for that particular project, subject to the notice and opportunity to repair
provisions of Paragraph 9.1."

14.      Paragraph 9.1 (Termination by the Regents) of the License Agreement is
         deleted in its entirety and replaced with the following:

                                       5
<PAGE>

         "9.1 Subject to Paragraph 5.11, if Licensee should violate or fail
to perform any term or covenant of this Agreement, then The Regents may give
written notice of such default ("Notice of Default") to Licensee. If Licensee
should fail to repair such default within sixty (60) days after the date such
notice takes effect, The Regents will have the right to terminate this
Agreement and the licenses herein by a second written notice ("Notice of
Termination") to Licensee. If a Notice of Termination is sent to Licensee,
this Agreement will automatically terminate on the date such notice takes
effect. Such termination will not relieve Licensee of its obligation to pay
any royalty or license fees owing at the time of such termination and will
not impair any accrued right of The Regents. These notices will be subject to
Article 18 (Notices)."

15.      Paragraph 18.1 (Notices) of the License Agreement is deleted in its
         entirety and replaced with the following:

         "18.1 Any notice or payment required to be given to either party
will be deemed to have been properly given and to be effective:

               18.1a    on the date of delivery if delivered in person;

               18.1b    on the date of mailing if mailed by first-class
                        certified mail, postage paid; or

               18.1c    on the date of mailing if mailed by any global express
                        carrier service that requires the recipient to sign the
                        documents demonstrating the delivery of such notice of
                        payment;

to the respective addresses given below, or to another address as designated
in writing by the party changing its prior address.

In the case of Licensee:          Ben-Abraham Technologies, Inc.
                                  175 Olde Half Day Road, Suite 123
                                  Lincolnshire, Illinois 60069
                                  Telephone: (847) 793-2434
                                  Facsimile: (847) 793-2435
                                  Attention: Stephen M. Simes
                                             President & CEO

In the case of The Regents:       The Regents of the University of California
                                  Office of the President
                                  Office of Technology Transfer
                                  1111 Franklin Street, 5th Floor
                                  Oakland, California 94607-5200
                                  Telephone: (510) 587-6000
                                  Facsimile: (510) 587-6090
                                  Attention: Executive Director
                                             Office of Technology Transfer
                                             Referring to: U.C. Case No. 89-204

                                       6
<PAGE>

         In Witness Whereof, both The Regents and the Licensee have executed
this Amendment, in duplicate originals, by their respective officers hereunto
duly authorized, on the day and year hereinafter written.

              BEN-ABRAHAM                            THE REGENTS OF THE
            TECHNOLOGIES INC.                     UNIVERSITY OF CALIFORNIA
By        /s/ Stephen M. Simes                By    /s/ Terence A. Feuerborn
  ------------------------------------          --------------------------------
                (Signature)                           (Signature)
Name    Stephen M. Simes                      Name   Terence A. Feuerborn
    ----------------------------------
Title      President & CEO                    Title   Executive Director,
    ----------------------------------                Research Administration
                                                      and Technology Transfer

Date      10/22/99                            Date     10/26/99
    ----------------------------------            ------------------------------












                    Approved as to legal form: /s/ Edwin H. Baker   10/22/99
                                              ---------------------------------
                                              Edwin H. Baker               Date
                                              University Counsel
                                              Office of General Counsel


                                       7